Positive Airway Pressure for Usual Interstitial Pneumonia

Phase-Based Progress Estimates
University of Arizona, Tucson, AZ
Usual Interstitial Pneumonia+7 More
Positive Airway Pressure - Device
All Sexes
What conditions do you have?

Study Summary

This trial will study whether using CPAP to treat sleep apnea can improve symptoms in patients with idiopathic pulmonary fibrosis. Positive Airway Pressure is used to treat Usual Interstitial Pneumonia. Positive Airway Pressure has previously been approved by the FDA for a different condition. No patients in this trial will be given a placebo instead of the treatment.

Eligible Conditions

  • Usual Interstitial Pneumonia
  • Obstructive Sleep Apnea (OSA)
  • Gastroesophageal Reflux

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Usual Interstitial Pneumonia

Study Objectives

1 Primary · 9 Secondary · Reporting Duration: 6 months

4-8 weeks
24hr-Esophageal pH
Biomarker of Lung Inflammation: CXCL13
Biomarker of Lung Inflammation: IL-8
Biomarker of Lung Inflammation: KL-6
Biomarker of Lung Inflammation: MMP1
Biomarker of Lung Inflammation: MMP7
Composite Biomarker Score
Esophageal pH During Sleep
6 months
Composite Biomarker Score at Six Months
FVC change

Trial Safety

Safety Progress

1 of 3

Other trials for Usual Interstitial Pneumonia

Trial Design

2 Treatment Groups

1 of 2
1 of 2
Active Control
Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Positive Airway Pressure · No Placebo Group · N/A

Experimental Group · 1 Intervention: Positive Airway Pressure · Intervention Types: Device
No CPAPNoIntervention Group · 1 Intervention: No CPAP · Intervention Types:
First Studied
Drug Approval Stage
How many patients have taken this drug
Positive Airway Pressure

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: University of Arizona · Tucson, AZ
Photo of az university of arizona 1Photo of az university of arizona 2Photo of tucson 3
2002First Recorded Clinical Trial
0 TrialsResearching Usual Interstitial Pneumonia
240 CompletedClinical Trials

Who is running the clinical trial?

University of ArizonaLead Sponsor
447 Previous Clinical Trials
153,961 Total Patients Enrolled
Boehringer IngelheimIndustry Sponsor
2,373 Previous Clinical Trials
9,768,327 Total Patients Enrolled
Sachin Chaudhary, MDPrincipal InvestigatorUniversity of Arizona

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a confirmed diagnosis of IPF based on the 2018 IPF guidelines.
You have a high likelihood of OSA based on the STOP-BANG measure, with a score of 3 or greater.
You are able to comply with CPAP treatment.
You are willing to complete all study measurements and assessments in compliance with the protocol.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.